Key Takeaways:
Skye Bioscience's $125 million acquisition of Redx Pharma creates Fibrx Therapeutics, a Nasdaq-listed fibrosis specialist targeting fibrostenotic Crohn's disease — a condition with no approved therapeutic options beyond surgery.
"This transaction gives Redx the capital and the platform to progress our pipeline and deliver the Phase 2 program for our lead asset, RXC008, a GI-restricted pan-ROCK inhibitor," Lisa Anson, Redx's chief executive officer, said. "We are excited to be launching Fibrx as a clinical-stage fibrosis-focused company."
The deal, structured as a scheme of arrangement under Part 26 of the UK Companies Act 2006, is expected to close in Q4 2026, subject to shareholder and regulatory approvals. The financing package includes a $68 million PIPE from Abingworth, British Business Bank, NEXTBio Capital, 5AM Ventures and Redmile; a $36 million Series A led by Abingworth; and a $22 million committed equity line facility from a Redmile-affiliated fund. Following closing, pre-transaction Redx holders will own 46.17 percent of the combined company, financing investors 48.45 percent, and Skye holders 5.38 percent, with 934,235,920 shares outstanding on a fully diluted basis.
The combined company's cash is expected to fund operations into 2029, through topline data from the RXC008 Phase 2 study expected in H2 2028. RXC008 holds FDA Fast Track designation granted in January 2026 and an open US Investigational New Drug application.
RXC008 Phase 2 Data Expected in H2 2028
RXC008 is a potential first-in-class GI-restricted pan-ROCK inhibitor designed to directly target fibrosis in stricturing Crohn's disease. Phase 1 data presented at the European Crohn's and Colitis Organization congress and Digestive Disease Week in 2025 showed favorable tolerability and tissue exposure with no clinically relevant systemic breakthrough or hypotension, and no serious adverse events. Pre-clinical studies demonstrated the potential to reverse GI-tract fibrosis, which would represent a shift from a standard of care that relies on surgical intervention.
The Redx pipeline extends beyond RXC008. Zelasudil (RXC007), a selective ROCK2 inhibitor, completed a signal-searching Phase 2 program in idiopathic pulmonary fibrosis and has potential in interstitial lung diseases, MASH and cancer-associated fibrosis. A pre-clinical Discoidin Domain Receptor program targets chronic kidney disease.
Skye's legacy asset, nimacimab, a CB1 receptor inhibitor developed for obesity, was discontinued in Q2 2026 after the company reviewed the evolving anti-obesity market. Pre-transaction Skye shareholders will receive contingent value rights entitling them to 90 percent of net proceeds from any monetization of nimacimab and its intellectual property during the 12 months following closing. Certain Redx shareholders receive CVRs covering 100 percent of net proceeds from legacy and partnered assets over 15 years.
The combined company will be led by Redx's management team and board, headquartered in Alderley Park, UK. Punit Dhillon, Skye's president and CEO, said the transaction provides Skye shareholders "a compelling opportunity to realize both short- and long-term value creation through Redx's novel anti-fibrotic therapies."
Stifel acted as exclusive financial advisor to Skye, with Morrison & Foerster as legal counsel. Wedbush PacGrow advised Redx, with Cooley as legal counsel. Leerink Partners and MTS Health Partners served as placement agents for the PIPE, with MTS also handling the Series A.
For investors, the deal transforms Skye from a single-asset obesity play into a fibrosis-focused platform with a Nasdaq listing and institutional backing. The $125 million capital injection provides a runway through key clinical milestones, but the combined company's value hinges on RXC008's Phase 2 results, which carry inherent clinical risk. The CVR structure preserves some upside for Skye shareholders from nimacimab while shifting the primary value driver to Redx's fibrosis pipeline.
This article is for informational purposes only and does not constitute investment advice.
